Compound tracker
RE104 / luvesilocin.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
3 trial rows 1 update rows Latest checked: May 17, 2026 All trials Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Check each source note before turning a row into a claim.
Backlinks
This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.
Completed / Not yet recruiting / Recruiting
Statuses seen
Trial rows
NCT07489651 Phase 2 Not yet recruiting updated May 15, 2026
- Condition
- Generalized Anxiety Disorder
- Sponsor / institution
- Reunion Neuroscience Inc
- Start date
- Apr 1, 2026
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; not-yet-recruiting Phase 2 status is investigational pipeline evidence, not approval, access, label, reimbursement, or efficacy/safety proof. Registry first/last posted 2026-03-24: randomized triple-masked placebo-controlled Phase 2; estimated n=64; single subcutaneous RE104 30mg vs placebo; primary endpoint HAM-A total-score change at Week 4; estimated completion 2027-04.
NCT07002034 Phase 2 Recruiting updated May 15, 2026
- Condition
- Adjustment Disorder in patients with cancer and other medical illnesses
- Sponsor / institution
- Reunion Neuroscience Inc
- Start date
- Jul 30, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; recruiting Phase 2 status is investigational pipeline evidence, not approval, access, label, reimbursement, or efficacy/safety proof. Registry last update posted 2026-05-06: randomized triple-masked parallel dose-controlled Phase 2; estimated n=100; single subcutaneous RE104 30mg vs 1.5mg; primary endpoint MADRS total-score change Day 7; estimated completion 2026-12.
NCT06342310 Phase 2 Completed updated May 15, 2026
- Condition
- Postpartum Depression
- Sponsor / institution
- Reunion Neuroscience Inc
- Start date
- Jun 14, 2024
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry and company-presentation schedule watch only; completed Phase 2 status and company-reported presentation plans do not establish approval, label, reimbursement, access, independent efficacy/safety confirmation, or Phase 3 success. Registry last update posted 2026-05-14: completed multicenter randomized triple-masked parallel dose-controlled Phase 2 in postpartum depression; actual n=84; single subcutaneous RE104 30mg vs 1.5mg; primary endpoint MADRS total-score change Day 7.
Related updates
May 17, 2026 Trial Update Company
Last checked: 2026-05-17 07:00 UTC. Reunion May 11 release still verifies RE104/luvesilocin RECONNECT presentation schedule only: APA poster May 18 and ASCP oral May 26. Actual APA/ASCP artifacts/data materials were not verified in this pass. Claim boundary: company schedule/pipeline watch only; no approval/access/final efficacy/safety upgrade.
Source/tracker note
Reunion release excerpt: ASCP Pharmaceutical Pipeline Session May 26, 2026 2:00-2:10 PM ET; APA poster titled RE104: A Novel Psychedelic Agent for Postpartum Depression. Actual meeting materials pending.
Conditions touched
Adjustment Disorder in patients with cancer and other medical illnessesGeneralized Anxiety DisorderPostpartum Depression